Replimune Faces Critical Juncture in FDA Showdown

Biotech firm Replimune confronts a pivotal moment for its future as it engages in a decisive Type-A meeting with U.S. regulators today. The company’s chief executive, Sushil Patel, has issued a stark warning that the entire RP1 program for melanoma treatment will become unsustainable without securing an accelerated approval pathway.

The crucial dialogue with the Food and Drug Administration commenced at 7:20 AM Eastern Time this morning. Replimune has presented comprehensive Read more...

@ boerse-global.de

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt anmelden.